OrigiMed - About the company
OrigiMed is a series B company based in Shanghai (China), founded in 2016 by Catherine Qin and Hui Kang. It operates as a Genetics-based personalized cancer counseling. OrigiMed has raised $10M in funding from IDG Capital and Grand Flight Investment. The company has 684 active competitors, including 179 funded and 137 that have exited. Its top competitors include companies like Guardant Health, Natera and Seer.
Company Details
Genetics-based personalized cancer counseling. By using next-generation high-throughput sequencing technologies, the company carries out comprehensive diagnostics for cancer patients to detect types of cancer. Based on the genetic profile of the patient, the company offers guidance on treatment options and helps patients in better understanding the disease.
Key Metrics
Founded Year
2016
Location
Shanghai, China
Stage
Series B
Total Funding
$10M in 4 rounds
Latest Funding Round
Investors
Ranked
148th among 684 active competitors
Similar Companies
Sign up to download OrigiMed's company profile
OrigiMed's funding and investors
OrigiMed has raised a total funding of $10M over 4 rounds. Its latest funding round was a Series B round on Jan 03, 2019 for $*****. 1 investor participated in its latest round. OrigiMed has 6 institutional investors.
Here is the list of recent funding rounds of OrigiMed:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 03, 2019 | 5105359 | Series B | 6365122 | 9981431 | 4154742 | 8141595 |
Nov 23, 2018 | 7499534 | Series A | 2796675 | 3757420 | 6692091 | |
Sep 20, 2016 | 7127303 | Seed | 3940555 | 7689531 |
View details of OrigiMed's funding rounds and investors
OrigiMed's founders and board of directors
Founder? Claim ProfileThe founders of OrigiMed are Catherine Qin and Hui Kang.
Here are the details of OrigiMed's key team members:
- Catherine Qin: Co-Founder of OrigiMed.
- Hui Kang: Co-Founder of OrigiMed.
View details of OrigiMed's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
OrigiMed's Competitors and alternates
Top competitors of OrigiMed include Guardant Health, Natera and Seer. Here is the list of Top 10 competitors of OrigiMed, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | 72/100 | |
4th | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
5th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
6th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
7th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
8th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
9th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
10th | Maze Therapeutics 2018, Redwood City (United States), Public | Developer of genetic bio-markers in neurological, metabolic, and renal diseases | $496M | 66/100 | |
148th | Genetics-based personalized cancer counseling | $10M | 39/100 |
Looking for more details on OrigiMed's competitors? Click here to see the top ones
OrigiMed's Investments and acquisitions
OrigiMed has made no investments or acquisitions yet.
Reports related to OrigiMed
Here is the latest report on OrigiMed's sector:
News related to OrigiMed
•
CSCO Foundation, Ping An Health Insurance and OrigiMed Announced Strategic Partnership for Innovative Ecosystem of Precision MedicinePR Newswire•May 17, 2023•Csco, Ping An, OrigiMed
•
•
China approves NGS-based genomic alteration tumour test by OrigiMed & BayerBioSpectrum Asia•Aug 23, 2021•OrigiMed, Bayer
•
Takeda, OrigiMed to develop genomic based clinical treatment platformBioSpectrum Asia•Nov 12, 2020•OrigiMed, Takeda
•
•
•
CTONG-OrigiMed New Clinical Trial Sharing Platform Launched during the 3rd OrigiMed Summit for Cancer DiscoveryPR Newswire•May 24, 2019•OrigiMed, ctongonline.com
•
•
OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor ApplicationsPR Newswire•Jul 11, 2018•OrigiMed, Illumina
Are you a Founder ?
FAQs about OrigiMed
Explore our recently published companies
- Eburns Design - United States based, Unfunded company
- Retail Consulting Turkey - Turkey based, 2016 founded, Unfunded company
- Processed Food Industry - A B2B Magazine - India based, 1997 founded, Unfunded company
- DroneOD - United Kingdom based, 2025 founded, Unfunded company
- RiskApp - New York based, Unfunded company
- DataSOS Technologies - Ahmedabad based, 2011 founded, Unfunded company